Skip to main content

Table 2 Occurrence of adverse events among all patients before and after DFK administration

From: Real-world use of difelikefalin in hemodialysis patients at a large dialysis organization in the United States: a retrospective database study

All Patients (N = 715)

Adverse Event

Before DFK

(Treatments = 27,705)

n (%)a

After DFK

(Treatments = 25,141)

n (%)b

P-Value

Nausea

234 (0.8)

215 (0.9)

0.8486

Diarrhea

157 (0.6)

162 (0.6)

0.2297

Vomiting

25 (0.09)

34 (0.1)

0.1168

Headache

51 (0.2)

54 (0.2)

0.4122

Dizziness

26 (0.09)

48 (0.2)

0.0027

Trouble walking

0 (0)

0 (0)

—

Hyperkalemia

558 (2.0)

650 (2.6)

0.0001

  1. a% of adverse events out all treatments that occurred before DFK
  2. b% of adverse events out all treatments that occurred after DFK
  3. DFK, difelikefalin
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us